Skip to main content

Aveo Pharmaceuticals, Inc.

AVEODelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001325879

Aveo Pharmaceuticals, Inc. was delisted in 2023; its insiders filed their last Form 4 on Jan 19, 2023; 110 institutions reported holding it in 13F filings for Q4 2022, worth $375.1M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Aveo Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Aveo Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Aveo Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Bate KennethDirector375Jan 19, 20230
Evnin Anthony BDirector0Jan 19, 20230
Bailey Michael PPresident & CEO0Jan 19, 20230
Mayes, Gregory T.Director–Jan 19, 20230
Lucera ErickChief Financial Officer–Jan 19, 20230
Spring ScarlettDirector–Jan 19, 20230
Epperly CorinneDirector–Jan 19, 20230
Ferraresso MichaelChief Commercial Officer0Jan 19, 20230
Cullen Kevin JosephDirector–Jan 19, 20230
Ledell JebediahChief Operating Officer–Jan 19, 20230
NEA Partners 15, L.P.10% Owner0Oct 21, 20220
Nea 15 GP, LLC10% Owner0Oct 21, 20220
Sandell Scott D10% Owner386IndirectOct 21, 20220
Baskett Forest10% Owner3,220IndirectOct 21, 20220
Sonsini Peter W.10% Owner24IndirectOct 21, 20220
Florence Anthony A. Jr.10% Owner354IndirectOct 21, 20220
New Enterprise Associates 15, L.P.10% Owner0Oct 21, 20220
Makhzoumi Mohamad10% Owner559Oct 21, 20220
Growth Equity Opportunities Fund IV, LLC10% Owner0Oct 21, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 3, 2021 (view filing)Sep 12 daysBailey Michael PPresident & CEOPPurchase+15.0K$6.48+$97.2K+43.7%49.3K after
Aug 11, 2021 (view filing)Aug 101 dayFerraresso MichaelChief Commercial OfficerPPurchase+2.61K$5.75+$15.0K+45.7%8.32K after